CytomX Therapeutics Inc
CytomX Therapeutics Inc (CTMX) Historical Volatility
CTMX's 30 day historical volatility is 67.10%, in the 46th percentile of readings over the past year. This is an average percentile, meaning CytomX Therapeutics Inc shares have moved roughly in line with their typical range. CTMX's 30 day implied volatility sits at 219.29%, with an IV Rank of 88.49%, leaving IV 152.19 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 5, 2026.
Read more
Tracking CTMX historical volatility helps you see how much CytomX Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CTMX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CTMX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CTMX's 30 day historical volatility, or CTMX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CTMX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 5, 2026
As of Nov 5, 2026
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →